The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

The Tremfya (trem-FYE-ah) ad starts with a woman in a dark room with ... are considered to have a major interaction with ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

As pharmaphorum recently reported, the entrance of biosimilars to Humira is a significant event ... company’s executive director and biosimilar commercial lead, Stephen Pagnotta, noted is ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...

AbbVie (NYSE:ABBV) is ticking up; according to a new Samsung Bioepis report, Humira's U.S. market share stays above 70% even with increasing biosimilar competition. Humira still dominated 96% of ...

Its Commercial Medicines Unit will then begin its procurement process for adalimumab, considering Humira as well as its biosimilar rivals. New contracts are then expected to be in place by ...

BSC provides pharmacy benefits for about 2.5 million Californians and processes about 40,000 prescriptions a year for Humira. Starting January 1, 2025, most BSC commercial members using Fresenius ...

Skyrizi, Rinvoq sales expected to surpass $31 billion by 2027 Humira sales decline 49% due to cheaper biosimilar competitors AbbVie earns $2.16 per share in Q4, beats estimates Jan 31 (Reuters ...